FDA Approves OncoMate MSI Dx as Pembrolizumab Companion Diagnostic in MSI-H Solid Tumors
Cancer Network,
That combination was evaluated in the phase 3 KEYNOTE-775 trial (NCT03517449) of 827 patients with previously treated advanced…
That combination was evaluated in the phase 3 KEYNOTE-775 trial (NCT03517449) of 827 patients with previously treated advanced…
The FDA approved the PCR-based OncoMate MSI Dx Analysis System to identify patients with microsatellite instability–high solid…
This Reading Room is a collaboration between MedPage Today® and: The combination of the multitargeted tyrosine kinase inhibitor…
Uterine cancer is the most common malignancy of the female genital tract in the United States.1 In 2024, the American Cancer…